A Comparison of Rocuronium 0.3 mg/kg, and 0.9 mg/kg for Induction of Anesthesia in Elderly Patients.

Anesthesia Clinical Trial

Official title:

A Single-blinded Multicenter Randomized Interventional Study of Rocuronium 0.3 mg/kg, and 0.9 mg/kg Comparing Onset Time, Duration of Action and Effect on Intubating Conditions in Elderly Patients (≥ 80 Years).

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04512313
• Other study ID #: H-19079175
• Status: Completed
• Phase: N/A
• Start date: December 17, 2020
• Est. completion date: May 25, 2021

Study information

• Verified date: June 2021
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The number of elderly patients above 80 years is increasing and a large proportion of these patients will require surgery and anesthesia. During anesthesia neuromuscular blocking agents (NMBA) are administered to facilitate intubating conditions and reduce the trauma to the larynx and vocal cords. There is a risk of residual neuromuscular block when using NMBAs like rocuronium. The aim of this study is to determine the onset time, duration of action and effect on intubating conditions after rocuronium 0.3 mg/kg and 0.9 mg/kg in patients with age ≥ 80 years.

Description:

The number of elderly patients (>80 years) is increasing and a large proportion of these patients will require surgery and anesthesia within the next decades. Elderly patients are at higher risk of major morbidity and mortality and are characterized by a reduction in cardiac output, liver function and renal function. These physiological changes influence pharmacodynamics and pharmacokinetics of drugs administered during anesthesia. Rocuronium is a nondepolarizing neuromuscular blocking drug with an onset time of approximately 70 s and a clinical duration of action of approximately 50 min. according to previous studies. During anesthesia rocuronium is administered to facilitate intubating conditions and reduce the trauma to the larynx and vocal cords. Rocuronium is primarily metabolized in the liver (70 % unmetabolized via the bile) and excreted via the kidneys. Onset time and duration of action of rocuronium should be assessed by objective neuromuscular monitoring. Also, this reduces the risk of residual neuromuscular block which is defined as a train of four (TOF) ratio less than 0.9. Especially elderly patients have a high incidence of residual neuromuscular block. The collected data regarding the effect of rocuronium in elderly patients may change the treatment so these patients receive the correct dose for optimal intubating conditions. Also, detection of duration of action of different doses of rocuronium may reduce the risk of residual block and postoperative respiratory complications The aim of this study is to determine the onset time, duration of action and effect on intubating conditions after rocuronium 0.3 mg/kg and 0.9 mg/kg in patients with age ≥ 80 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: May 25, 2021
• Est. primary completion date: May 18, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 80 Years and older

Eligibility

Inclusion Criteria:

• Age = 80
• Scheduled to elective surgery (expected duration time of surgery > 1 hour) under general anesthesia with intubation and use of rocuronium.
• American Society of Anesthesiologists (ASA) physical status classification I to III
• Informed consent (see appendix 1)
• Read and understand Danish

Exclusion Criteria:

• Neuromuscular disease
• Known allergy to rocuronium
• Prone position
• Indication for rapid sequence induction

Related Conditions & MeSH terms

• Anesthesia
• Delayed Emergence from Anesthesia
• Intubation Complication
• Neuromuscular Blockade
• Neuromuscular Blockade, Residual

Intervention

Drug:
• Rocuronium 0,3mg/kg
Rocuronium 0,3mg/kg at induction
• Rocuronium 0,9mg/kg
Rocuronium 0,9mg/kg at induction

Locations

Country	Name	City	State
Denmark	Rigshospitalet	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rocuronium onset time	Time from start of rocuronium injection to train-of-four (TOF) count of 0	intraoperative (From start of rocuronium injection to train-of-four (TOF) count of 0)
Secondary	Duration of action of rocuronium	Time from start of rocuronium injection to reappearance of TOF ratio > 0.9.	intraoperative (Time from start of rocuronium injection to reappearance of TOF ratio > 0.9.)
Secondary	Evaluation of intubating conditions ad modum Fuchs-Buder et al	Intubating conditions are rated by an intubating difficulty scale according to Fuchs-Buder et al.	intraoperative (From train-of-four (TOF) count of 0 till)